Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Crystal Ball For Drug Launch Success? Try Consensus Estimates

This article was originally published in The Pink Sheet Daily

Executive Summary

Consensus estimates can be a predictor of how a biopharma will perform during a drug launch, a Leerink Swann report shows, citing examples from the last ten years as proof.

You may also be interested in...



Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012

Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.

Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations

The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel